MedTrace Logo

BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

NCT07715136 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-07-20

No results posted yet for this study

Summary

This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).

Conditions

  • Inflammatory Myopathy

Interventions

BIOLOGICAL

ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T

Anti-BCMA, Anti-CD19 Compound CAR-T cells

Sponsors & Collaborators

  • iCell Gene Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07715136 on ClinicalTrials.gov